X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (30) 30
female (28) 28
oncology (24) 24
aged (22) 22
middle aged (22) 22
index medicus (19) 19
adult (18) 18
male (16) 16
treatment outcome (14) 14
hematology (12) 12
aged, 80 and over (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
chemotherapy (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
breast cancer (10) 10
survival analysis (9) 9
clinical trials (8) 8
breast neoplasms - drug therapy (7) 7
management (7) 7
therapy (7) 7
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
cancer (6) 6
care and treatment (6) 6
chronic myeloid leukemia (6) 6
drug administration schedule (6) 6
energy & fuels (6) 6
engineering, mechanical (6) 6
turbines (6) 6
analysis (5) 5
cyclophosphamide - administration & dosage (5) 5
epirubicin - administration & dosage (5) 5
fluorouracil - administration & dosage (5) 5
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (5) 5
pumps (5) 5
research (5) 5
survival (5) 5
breast neoplasms - pathology (4) 4
cancer therapies (4) 4
chemotherapy, adjuvant (4) 4
chronic myelogenous leukemia (4) 4
cml (4) 4
cyclophosphamide (4) 4
disease-free survival (4) 4
drehmoment (4) 4
hematology, oncology and palliative medicine (4) 4
italy (4) 4
medicine (4) 4
multivariate analysis (4) 4
neoplasm staging (4) 4
numerische strömungssimulation (4) 4
pyrimidines - administration & dosage (4) 4
pyrimidines - adverse effects (4) 4
pyrimidines - therapeutic use (4) 4
recommendations (4) 4
remission induction (4) 4
surgery (4) 4
thermodynamics (4) 4
tumors (4) 4
adolescent (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
betriebsbedingung (3) 3
betriebszustand (3) 3
breast neoplasms - diagnosis (3) 3
breast neoplasms - mortality (3) 3
breast neoplasms - surgery (3) 3
carboplatin - administration & dosage (3) 3
carcinoma (3) 3
comorbidity (3) 3
cyclophosphamide - adverse effects (3) 3
dasatinib (3) 3
dose-response relationship, drug (3) 3
doxorubicin (3) 3
drug dosages (3) 3
efficacy (3) 3
electric power generation (3) 3
epirubicin - adverse effects (3) 3
erbb-2 protein (3) 3
fluid dynamics (3) 3
fluorouracil - adverse effects (3) 3
follow-up (3) 3
green & sustainable science & technology (3) 3
hemic and lymphatic diseases (3) 3
imatinib mesylate (3) 3
impeller (3) 3
kaplan-meier estimate (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - epidemiology (3) 3
medicine & public health (3) 3
neoplasm grading (3) 3
numerische analyse (3) 3
optimization (3) 3
paclitaxel (3) 3
paclitaxel - administration & dosage (3) 3
particle image velocimetry (3) 3
patients (3) 3
piperazines - therapeutic use (3) 3
prognosis (3) 3
protein kinase inhibitors - administration & dosage (3) 3
protein kinase inhibitors - adverse effects (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9980, pp. 1863 - 1872
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 396 - 405
Journal Article
ENERGIES, ISSN 1996-1073, 07/2016, Volume 9, Issue 7, pp. 534 - 534
To achieve the carbon free electricity generation target for 2050, the penetration of renewable energy sources should further increase. To address the impacts... 
STORAGE | SYSTEM | OFF-DESIGN CONDITIONS | ROTATING STALL | ENERGY & FUELS | hydro plant control | CENTRIFUGAL PUMP | dynamic response of hydro plants | VOLUTE | IMPELLER | FLOW STRUCTURE | adjustable speed hydro plants | pump-turbine | Ramps | Electric power generation | Reduction | Control | Pumping | Full load | Carbon | Channels
Journal Article
Drugs & Aging, ISSN 1170-229X, 8/2013, Volume 30, Issue 8, pp. 629 - 637
A large number of chronic myeloid leukemia (CML) patients are treated with imatinib mesylate outside of clinical trials, which may not be representative of... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Geriatrics/Gerontology | SURVIVAL | CML | MYELOPROLIFERATIVE DISORDERS | SAFETY | TYROSINE KINASE | PROGNOSTIC SCORE | FOLLOW-UP | PHARMACOLOGY & PHARMACY | MESYLATE THERAPY | AGE | GERIATRICS & GERONTOLOGY | Piperazines - administration & dosage | Follow-Up Studies | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Benzamides - therapeutic use | Neoplasm Grading | Antineoplastic Agents - adverse effects | Aged, 80 and over | Aging | Female | Retrospective Studies | Benzamides - adverse effects | Comorbidity | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Protein Kinase Inhibitors - administration & dosage | Leukemia, Myeloid, Chronic-Phase - epidemiology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Italy - epidemiology | Aged | Drug Monitoring | Cohort Studies | Drug therapy | Chronic myeloid leukemia | Research | Index Medicus
Journal Article
Information Sciences, ISSN 0020-0255, 04/2015, Volume 299, pp. 337 - 378
•A novel paradigm of the original particle swarm concept is presented.•Two types of agents are identifiable in the swarm: explorers and settlers.•The particles... 
Optimization algorithms | Particle swarm optimization | Swarm intelligence | REAL-PARAMETER OPTIMIZATION | COMPUTER SCIENCE, INFORMATION SYSTEMS | DIFFERENTIAL EVOLUTION | Mathematical optimization | Algorithms | Settlers | Tasks | Searching | Adaptive algorithms | Mathematical models | Differentiation | Acceleration
Journal Article
Sustainable Cities and Society, ISSN 2210-6707, 10/2019, p. 101890
Journal Article
Journal of Fluids Engineering, ISSN 0098-2202, 02/2016, Volume 138, Issue 2, pp. 021105 - 021105-12
The most common mechanical equipment adopted in the new generation of pumped-hydro power plants is represented by reversible pump-turbines (RPT), required to... 
ENGINEERING, MECHANICAL | ROTATING STALL | Usage | Computer-generated environments | Research | Fluid dynamics | Computer simulation | Turbines | Rejection | Electric power generation | Numerical analysis | Blades | Constants | Unsteady | Brakes
Journal Article
Journal of Fluids Engineering, ISSN 0098-2202, 02/2018, Volume 140, Issue 2, pp. 021114 - 021114-9
This paper presents the simulation of the dynamic behavior of variable speed pump–turbine. A power reduction scenario at constant wicket gate opening was... 
ENGINEERING, MECHANICAL
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 06/2016, Volume 91, Issue 6, pp. 617 - 622
Journal Article
Renewable and Sustainable Energy Reviews, ISSN 1364-0321, 10/2018, Volume 94, pp. 399 - 409
Journal Article
by De Placido, Sabino and Gallo, Ciro and De Laurentiis, Michelino and Bisagni, Giancarlo and Arpino, Grazia and Sarobba, Maria Giuseppa and Riccardi, Ferdinando and Russo, Antonio and Del Mastro, Lucia and Cogoni, Alessio Aligi and Cognetti, Francesco and Gori, Stefania and Foglietta, Jennifer and Frassoldati, Antonio and Amoroso, Domenico and Laudadio, Lucio and Moscetti, Luca and Montemurro, Filippo and Verusio, Claudio and Bernardo, Antonio and Lorusso, Vito and Gravina, Adriano and Moretti, Gabriella and Lauria, Rossella and Lai, Antonella and Mocerino, Carmela and Rizzo, Sergio and Nuzzo, Francesco and Carlini, Paolo and Perrone, Francesco and Accurso, Antonello and Agostara, Biagio and Aieta, Michele and Alabiso, Oscar and Alicicco, Maria Grazia and Amadori, Dino and Amaducci, Laura and Amiconi, Gianna and Antuzzi, Giustino and Ardine, Mara and Ardizzoia, Antonio and Aversa, Caterina and Badalamenti, Giuseppe and Barni, Sandro and Basurto, Carlo and Berardi, Rossana and Bergamasco, Cinzia and Bidoli, Paolo and Bighin, Claudia and Biondi, Edoardo and Bisagni, Giancarlo and Boni, Corrado and Borgonovo, Karen and Botta, Mario and Bravi, Stefano and Bruzzi, Paolo and Buono, Giuseppe and Butera, Alfredo and Caldara, Alessia and Candeloro, Giampiero and Cappelletti, Claudia and Cardalesi, Cinzia and Carfora, Elisabetta and Cariello, Anna and Carrozza, Francesco and Cartenì, Giacomo and Caruso, Michele and Casadei, Virginia and Casanova, Claudia and Castori, Luigi and Cavanna, Luigi and Cavazzini, Giovanna and Cazzaniga, Marina and Chilelli, Mario and Chiodini, Paolo and Chiorrini, Silvia and Ciardiello, Fortunato and Ciccarese, Mariangela and Cinieri, Saverio and Clerico, Mario and Coccaro, Mariarosa and Comande, Mario and Corbo, Claudia and Cortino, Giuseppina and Cusenza, Stefania and Daniele, Gennaro and D'arco, Alfonso Maria and D'auria, Giuliana and Dazzi, Claudio and De Angelis, Carmine and de Braud, Filippo and De Feo, Gianfranco and De Matteis, Andrea and De Tursi, Michele and Di Blasio, Anna and di Lucca, Giuseppe and Di Lullo, Liberato and Di Rella, Francesca and Di Renzo, Gianfranco and Di Stefano, Pia and ... and GIM Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 474 - 485
Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly... 
SYSTEM | THERAPY | EFFICACY | ONCOLOGY | FOLLOW-UP | POSTMENOPAUSAL WOMEN | COMBINATION | AROMATASE INHIBITORS | Breast cancer | Product development | Tamoxifen | Analysis
Journal Article